Tivdak Disease Interactions

Avoid the use of tisotumab vedotin in patients with moderate or severe hepatic impairment.

Ocular adverse events are very common in patients receiving treatment with tisotumab vedotin. Patients with baseline visual disturbances should be monitored and if any symptoms worsen should be evaluated promptly by an eye care provider. Reduce dosage, withhold or permanently discontinue treatment based on the severity of the symptoms.

Patients receiving treatment with tisotumab vedotin may have peripheral neuropathy adverse reactions. Patients with preexisting peripheral neuropathy should be monitored. Reduce dosage, withhold, or permanently discontinue treatment based on the severity of symptoms.